Skip to content
Disclosery

EXANE DERIVATIVES: CHRW position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on CHRW, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 18 CHRW shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 18 shares
    Change vs previous 13F 0 shares

    <0.01% of the 13F portfolio, value $1,824.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 18 shares
    Change vs previous 13F -8,298 shares

    <0.01% of the 13F portfolio, value $1,939.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 8,316 shares
    Change vs previous 13F +4,110 shares

    0.22% of the 13F portfolio, value $895,019.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 4,206 shares
    Change vs previous 13F -375 shares

    0.09% of the 13F portfolio, value $365,909.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 4,581 shares
    Change vs previous 13F -1,737 shares

    0.1% of the 13F portfolio, value $424,283.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 6,318 shares
    Change vs previous 13F not available

    0.18% of the 13F portfolio, value $602,900.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).